The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
Open accessAbstract
Early-onset schizophrenia-spectrum (EOSS) disorders (onset of psychotic symptoms before 18 years of age) represent a severe variant associated with significant chronic functional impairment and poor response to antipsychotic treatment. All drugs with proven antipsychotic effects block dopamine D(2) receptors to some degree. The ongoing development of the dopamine and other neurotransmitter receptor systems during childhood and adolescence may affect clinical response and susceptibility to side effects in youth. A literature search was conducted of clinical trials of antipsychotics in children and adolescents with EOSS disorders between 1980 and 2007 from the Medline database, reference lists, and conference proceedings. Trials were limited to double-blind studies of duration of 4 or more weeks that included 15 or more patients. Ten clinical trials were identified. Antipsychotic medications were consistently found to reduce the severity of psychotic symptoms in children and adolescents when compared with placebo. The superiority of clozapine has been now demonstrated relative to haloperidol, standard-dose olanzapine, and "high-dose" olanzapine for EOSS disorders. However, limited comparative data are available regarding whether there are differences among the remaining second-generation antipsychotics (SGAs) in clinical effectiveness. The available data from short-term studies suggest that youth might be more sensitive than adults to developing antipsychotic-related adverse side effects (eg, extrapyramidal side effects, sedation, prolactin elevation, weight gain). In addition, preliminary data suggest that SGA use can lead to the development of diabetes in some youth, a disease which itself carries with it significant morbidity and mortality. Such a substantial risk points to the urgent need to develop therapeutic strategies to prevent and/or mitigate weight gain and diabetes early in the course of treatment in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · cited 1×
“affinity for both dopamine D2 receptors as well as for serotonin 5-hydroxytryptamine (5-HT)2 and include clozapine, risperidone (and its active metabolite paliperidone), olanzapine, quetiapine, and ziprasidone.(39) In addition, aripiprazole, another novel antipsychotic that is a partial do-”
BackgroundChildhood-Onset Schizophrenia: A Double-blind Clozapine-Haloperidol Comparison
Kumra, S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830120020005 · Cited by 410
Self-citationRosenberg, D. R., & Lewis, D. A. (1995) · Journal of Comparative Neurology · doi:10.1002/cne.903580306 · Cited by 319
Benes, F. M. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.10.1014 · Cited by 268
Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison
Shaw, P., Sporn, A., Gogtay, N., Overman, G. P., Greenstein, D., Gochman, P., Tossell, J. W., Lenane, M., & Rapoport, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.721 · Cited by 225
Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods
McCLELLAN, J., SIKICH, L., FINDLING, R. L., FRAZIER, J. A., VITIELLO, B., HLASTALA, S. A., WILLIAMS, E., AMBLER, D., HUNT-HARRISON, T., MALONEY, A. E., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180691779 · Cited by 90
Self-citation
Cited by
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
“Growing evidence suggests that children and adolescents who take antipsychotic medication are at higher risk of weight gain and metabolic effects than adults who use the same drugs [32,36,79,80,103].”
BackgroundResultMetabolic syndrome in people with schizophrenia: a review
DE HERT, M., SCHREURS, V., VANCAMPFORT, D., & VAN WINKEL, R. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00199.x · Cited by 634
De Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2010.09.011 · Cited by 362
Maayan, L., & Correll, C. U. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0015 · Cited by 252
Escitalopram versus other antidepressive agents for depression
Cipriani, A., Santilli, C., Furukawa, T. A., Signoretti, A., Nakagawa, A., McGuire, H., Churchill, R., & Barbui, C. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006532.pub2 · Cited by 190
Metadata
- Authors
- Kumra, S., Oberstar, J. V., Sikich, L., Findling, R. L., McClellan, J. M., Vinogradov, S., & Charles Schulz, S.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-27
- Volume
- 34
- Issue
- 1
- Pages
- 60-71
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2136742651
- Cited by
- 186
- References
- 8
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia. https://app.cochat.ai/papers/10.1093/schbul/sbm109
- The paper
- Kumra, S., Oberstar, J. V., Sikich, L., Findling, R. L., McClellan, J. M., Vinogradov, S., & Charles Schulz, S. (2007). Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbm109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.